Looking Into Revvity's Recent Short Interest
Revvity To Present At Baird Global Healthcare Conference; Webcast At 12:15 PM ET
Revvity (RVTY) Gets a Hold From Wells Fargo
Reasons to Retain Revvity Stock in Your Portfolio for Now
Revvity, Inc. (NYSE:RVTY) Not Lagging Market On Growth Or Pricing
Jefferies Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $130
Jefferies analyst Brandon Couillard maintains $Revvity(RVTY.US)$ with a hold rating, and adjusts the target price from $115 to $130.According to TipRanks data, the analyst has a success rate of 64.0%
Revvity Initiated at Equal-Weight by Wells Fargo
Wells Fargo Initiates Coverage On Revvity With Equal-Weight Rating, Announces Price Target of $130
Revvity Analyst Ratings
Revvity Stock: Is Wall Street Bullish or Bearish?
RNAi Market and Technologies Industry Report 2024, With Company Profiles of Major Players Including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
Revvity to Present at Upcoming Investor Conferences
Some Investors May Be Willing To Look Past Revvity's (NYSE:RVTY) Soft Earnings
Revvity, Inc. (NYSE:RVTY) Is a Favorite Amongst Institutional Investors Who Own 81%
Life Science Tools and Reagents Market Report 2024, With Profiles of BD, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Merck, Promega, Qiagen, Revvity, Takara Bio and Thermo Fisher Scientific
Decoding Revvity Inc (RVTY): A Strategic SWOT Insight
Revvity | 10-Q: Q2 2024 Earnings Report
While the S&P 500 Sinks, Kellanova Stock Is Rising. Here's Why. -- Barrons.com
S&P 500 Futures Decline In Premarket Trading; First Fincl Bankshares, MicroStrategy Lag
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)